This December IONIS Pharmaceuticals announced their groundbreaking results from the first Huntingtin lowering trial in humans (called IONIS-HTTRx). At the same time it was announced that Roche was going to take over the trial. Here is a message from their team:
Dear members of the Huntington’s Community,
We are delighted that IONIS-HTTRx is entering the next stage of clinical development.
The Ionis and Roche teams have been collaborating closely on the IONIS-HTTRx programme since 2013. Our team at Roche will now be leading the programme going forward. We feel honoured and privileged to take on this important responsibility.
Understandably, many of you are eager to learn more about the next steps for IONIS-HTTRx; we are working diligently to finalise these plans as quickly as possible and will keep you updated as these develop. Our immediate focus is to ensure a seamless transition of the programme from Ionis to Roche.
We look forward to continue and expand our partnership with the HD Community in the development of IONIS-HTTRx.
Wishing you all a very happy Festive Season, and all the best for 2018!
The Roche team